

| | | | | |
|---|--|---|---------------------------------------|-------------------------------|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 14875-153US1 | Application No. 10/551,504 |
| O I P E Information Disclosure Statement by Applicant MAY 23 2007 (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant Hiroyuki Tsunoda et al. Filing Date May 12, 2006 | | |
| | | | | Group Art Unit 1644 |

U.S. Patent Documents

| Examiner Initial | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | Filing Date If Appropriate |
|------------------|-----------|-----------------|------------------|------------------|-------|----------|----------------------------|
| | A1 | 5,877,291 | 04/20/1995 | Mezes et al. | | | |
| | A2 | 6,183,744 | 02/06/2001 | Goldenberg | | | |
| | A3 | 6,323,000 | 11/07/2001 | Briggs et al. | | | |
| | A4 | 6,342,220 | 01/29/2002 | Adams et al. | | | |
| | A5 | 6,368,596 | 04/09/2002 | Ghetie et al. | | | |
| | A6 | 6,683,157 | 01/27/2004 | Briggs et al. | | | |
| | A7 | 2001/0006796 | 07/05/2001 | Briggs et al. | | | |
| | A8 | 2002/0193571 | 12/19/2002 | Carter et al. | | | |
| | A9 | 2003/0073161 | 04/17/2003 | Briggs et al. | | | |
| | A10 | 2003/0148409 | 08/07/2003 | Rossi et al. | | | |
| | A11 | 2004/0091475 | 05/13/2004 | Tsuchiya et al. | | | |
| | A12 | 2004/0242847 | 12/02/2004 | Fukushima et al. | | | |
| | A13 | 2006/0189794 | 08/24/2006 | Tsuchiya et al. | | | |
| | A14 | 2006/0275301 | 12/07/2006 | Ozaki et al. | | | |
| | A15 | 2007/0003556 | 01/07/2007 | Tsuchiya et al. | | | |

Foreign Patent Documents or Published Foreign Patent Applications

| Examiner Initial | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation | |
|------------------|-----------|-----------------|------------------|--------------------------|-------|----------|------------------|----|
| | | | | | | | Yes | No |
| * | A16 | JP 7-503622 | 04/20/1995 | Japan | | | See A1 | |
| * | A17 | JP 10-505231 | 05/26/1998 | Japan | | | See A22 | |
| * | A18 | JP 2001-506135 | 05/15/2001 | Japan | | | See A7 | |
| * | A19 | JP 2001-513099 | 09/11/2001 | Japan | | | See A4 | |
| | A20 | JP 2001-518030 | 10/16/2001 | Japan | | | See A26 | |
| | A21 | JP 2002-544173 | 12/24/2002 | Japan | | | See A30 | |
| | A22 | WO 96/04925 | 02/22/1996 | WIPO | | | | |
| | A23 | WO 97/31108 | 08/28/1997 | WIPO | | | English abstract | |
| | A24 | WO 98/28331 | 07/02/1998 | WIPO | | | | |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.S./

| | |
|--|-----------------|
| Examiner Signature | Date Considered |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | | |
|--|--|--|---------------------------------------|-------------------------------|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 14875-153US1 | Application No. 10/551,504 |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant Hiroyuki Tsunoda et al. | | |
| | | Filing Date May 12, 2006 | Group Art Unit 1644 | |

| Foreign Patent Documents or Published Foreign Patent Applications | | | | | | | |
|--|-----------|-----------------|------------------|--------------------------|---------------|----------|------------------|
| Examiner Initial | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation |
| | | | | | | | Yes No |
| /L.S./ | A25 | WO 98/41641 | 09/24/1998 | WIPO | | | |
| /L.S./ | A26 | WO 98/42378 | 10/01/1998 | WIPO | | | |
| /L.S./ | A27 | WO 99/02567 | 01/21/1999 | WIPO | | | |
| | A28 | WO 99/10494 | 03/04/1999 | WIPO | | | |
| | A29 | WO 00/67795 | 11/16/2000 | WIPO | | | |
| | A30 | WO 01/64713 | 09/07/2001 | WIPO | | | |
| | A31 | WO 01/66737 | 09/13/2001 | WIPO | | | |
| | A32 | WO 01/74388 | 10/11/2001 | WIPO | | | |
| | A33 | WO 01/79494 | 10/25/2001 | WIPO | | | English abstract |
| | A34 | WO 01/97858 | 12/27/2001 | WIPO | | | |
| | A35 | WO 02/04021 | 01/17/2002 | WIPO | | | |
| | A36 | WO 02/22212 | 03/21/2002 | WIPO | | | |
| | A37 | WO 02/33072 | 04/25/2002 | WIPO | | | See A9 |
| /L.S./ | A38 | WO 02/33073 | 04/25/2002 | WIPO | | | See A11 |
| /L.S./ | A39 | WO 03/033654 | 04/24/2003 | WIPO | | | |
| /L.S./ | A40 | WO 03/104425 | 12/18/2003 | WIPO | | | |
| /L.S./ | A41 | WO 2004/033499 | 04/22/2004 | WIPO | | | X |
| /L.S./ | A42 | WO 2004/081048 | 09/23/2004 | WIPO | Abstract only | | X |
| /L.S./ | A43 | WO 2004/087763 | 10/14/2004 | WIPO | Abstract only | | X |

| Other Documents (include Author, Title, Date, and Place of Publication) | | |
|--|-----------|--|
| Examiner Initial | Desig. ID | Document |
| /L.S./ | A44 | Ballmaier et al., "c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia," <i>Blood</i> , 97:139-146 (2001) |
| /L.S./ | A45 | Brinkmann et al., "FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity," <i>Curr. Opin. Immunol.</i> , 14:569-575 (2002) |
| /L.S./ | A46 | Bruenke et al., "A recombinant bispecific single-chain Fv antibody against HLA class II and FcγRIII (CD16) triggers effective lysis of lymphoma cells," <i>Br. J. Haematol.</i> , 125:167-179 (2004) |
| /L.S./ | A47 | Clark, "CD22, a B Cell-Specific Receptor, Mediates Adhesion and Signal Transduction," <i>J. Immunol.</i> , 150:4715-4718 (1993) |

| | |
|--|-----------------|
| Examiner Signature | Date Considered |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | |
|--|--|---------------------------------------|-------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 14875-153US1 | Application No. 10/551,504 |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant Hiroyuki Tsunoda et al. | |
| | | Filing Date May 12, 2006 | Group Art Unit 1644 |

| Other Documents (include Author, Title, Date, and Place of Publication) | | | |
|--|-----------|---|--|
| Examiner Initial | Desig. ID | Document | |
| /L.S./ | A48 | Co et al., "A Humanized Antibody Specific for the Platelet Integrin gpIIb/IIIa," <i>J. Immunol.</i> , 152:2968-2976 (1994) | |
| /L.S./ | A49 | Daniel et al., "Induction of Apoptosis in Human Lymphocytes by Human Anti-HLA Class I Antibodies," <i>Transplantation</i> , 75:1380-1386 (2003) | |
| /L.S./ | A50 | De Felice et al., "Differential regulatory role of monomorphic and polymorphic determinants of histocompatibility leukocyte antigen class I antigens in monoclonal antibody OKT3-induced T cell proliferation," <i>J. Immunol.</i> , 139:2683-2689 (1987) | |
| /L.S./ | A51 | DeNardo et al., "Anti-HLA-DR/anti-DOTA Diabody Construction in a Modular Gene Design Platform: Bispecific Antibodies for Pretargeted Radioimmunotherapy," <i>Cancer Biother. Radiopharm.</i> , 16:525-535 (2001) | |
| /L.S./ | A52 | Deng et al., "An Agonist Murine Monoclonal Antibody to the Human c-Mpl Receptor Stimulates Megakaryocytopoiesis," <i>Blood</i> , 92:1981-1988 (1998) | |
| /L.S./ | A53 | Ebert et al., "Expression of Metallothionein II in Intestinal Metaplasia, Dysplasia, and Gastric Cancer," <i>Cancer Res.</i> , 60:1995-2001 (2000) | |
| /L.S./ | A54 | Elliott et al., "Activation of the Erythropoietin (EPO) Receptor by Bivalent Anti-EPO Receptor Antibodies," <i>J. Biol. Chem.</i> , 271:24691-24697 (1996) | |
| /L.S./ | A55 | Fayen et al., "Negative signaling by anti-HLA class I antibodies is dependent upon two triggering events," <i>Int. Immunol.</i> , 10:1347-1358 (1998) | |
| /L.S./ | A56 | Funaro et al., "Monoclonal antibodies and therapy of human cancers," <i>Biotechnol. Adv.</i> , 18:385-401 (2000) | |
| /L.S./ | A57 | Genestier et al., "Antibodies to HLA Class 1 $\alpha 1$ Domain Trigger Apoptosis of CD40-Activated Human B Lymphocytes," <i>Blood</i> , 90:726-735 (1997) | |
| /L.S./ | A58 | Genestier et al., "Caspase-dependent Ceramide Production in Fas- and HLA Class I-mediated Peripheral T Cell Apoptosis," <i>J. Biol. Chem.</i> , 273:5060-5066 (1998) | |
| /L.S./ | A59 | Genestier et al., "Fas-Independent Apoptosis of Activated T Cells Induced by Antibodies to the HLA Class I $\alpha 1$ Domain," <i>Blood</i> , 90:3629-3639 (1997) | |
| /L.S./ | A60 | Genestier et al., "T cell sensitivity to HLA class I-mediated apoptosis is dependent on interleukin-2 and interleukin-4," <i>Eur. J. Immunol.</i> , 27:495-499 (1997) | |
| /L.S./ | A61 | Ghetie et al., "Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells," <i>Proc. Natl. Acad. Sci. USA</i> , 94:7509-7514 (1997) | |
| /L.S./ | A62 | Goel et al., " ^{99m} Tc-Labeled Divalent and Tetraivalent CC49 Single-Chain Fv's: Novel Imaging Agents for Rapid In Vivo Localization of Human Colon Carcinoma," <i>J. Nucl. Med.</i> , 42:1519-1527 (2001) | |
| /L.S./ | A63 | Goel et al., "Genetically Engineered Tetraivalent Single-Chain Fv of the Pancarcinoma Monoclonal Antibody CC49: Improved Biodistribution and Potential for Therapeutic Application," <i>Cancer Res.</i> , 60:6964-6971 (2000) | |
| /L.S./ | A64 | Goto et al., "A Novel Membrane Antigen Selectively Expressed on Terminally Differentiated Human B Cells," <i>Blood</i> , 84:1922-1930 (1994) | |
| /L.S./ | A65 | Holliger et al., "Diabodies": Small bivalent and bispecific antibody fragments," <i>Proc. Natl. Acad. Sci. USA</i> , 90:6444-6448 (1993) | |

| | |
|--|-----------------|
| Examiner Signature | Date Considered |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | |
|--|--|---------------------------------------|-------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 14875-153US1 | Application No. 10/551,504 |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant Hiroyuki Tsunoda et al. | |
| | | Filing Date May 12, 2006 | Group Art Unit 1644 |

| Other Documents (include Author, Title, Date, and Place of Publication) | | | |
|--|-----------|--|--|
| Examiner Initial | Desig. ID | Document | |
| /L.S./ | A66 | Hu et al., "Minibody: A Novel Engineered Anti-Carcinoembryonic Antigen Antibody Fragment (Single-Chain Fv-C _H 3) Which Exhibits Rapid, High-Level Targeting of Xenografts," <i>Cancer Res.</i> , 56:3055-3061 (1996) | |
| /L.S./ | A67 | Hudson et al., "High avidity scFv multimers; diabodies and triabodies," <i>J. Immunol. Methods</i> , 231:177-189 (1999) | |
| /L.S./ | A68 | Kikuchi et al., "A bivalent single-chain Fv fragment against CD47 induces apoptosis for leukemic cells," <i>Biochem. Biophys. Res. Commun.</i> , 315:912-918 (2004) | |
| /L.S./ | A69 | Kimura et al., "2D7 diabody bound to the α2 domain of HLA class I efficiently induces caspase-independent cell death against malignant and activated lymphoid cells," <i>Biochem. Biophys. Res. Commun.</i> , 325:1201-1209 (2004) | |
| /L.S./ | A70 | Kipriyanov et al., "Effect of Domain Order on the Activity of Bacterially Produced Bispecific Single-chain Fv Antibodies," <i>J. Mol. Biol.</i> , 330:99-111 (2003) | |
| /L.S./ | A71 | Kortt et al., "Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting," <i>Biomol. Eng.</i> , 18:95-108 (2001) | |
| /L.S./ | A72 | Kreitman et al., "Cytotoxic Activity of Disulfide-stabilized Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) toward Fresh Malignant Cells from Patients with B-Cell Leukemias," <i>Clin. Cancer Res.</i> , 6:1476-1487 (2000) | |
| /L.S./ | A73 | Kulkarni et al., "Construction of a Single-Chain Antibody Derived From 5H7, A Monoclonal Antibody Specific for a Death Signaling Domain of Human Class I Major Histocompatibility Complex," <i>Transplant. Proc.</i> , 30:1081 (1998) | |
| /L.S./ | A74 | Kulkarni et al., "Programmed Cell Death Signaling Via Cell-Surface Expression of a Single-Chain Antibody Transgene," <i>Transplantation</i> , 69:1209-1217 (2000) | |
| /L.S./ | A75 | Lebrun et al., "Antibodies to the Extracellular Receptor Domain Restore the Hormone-insensitive Kinase and Conformation of the Mutant Insulin Receptor Valine 382," <i>J. Biol. Chem.</i> , 268:11272-11277 (1993) | |
| /L.S./ | A76 | Li et al., "The Epitope Specificity and Tissue Reactivity of Four Murine Monoclonal Anti-CD22 Antibodies," <i>Cell. Immunol.</i> , 118:85-99 (1989) | |
| /L.S./ | A77 | Matsuoka et al., "A Monoclonal Antibody to the α2 Domain of Murine Major Histocompatibility Complex Class I that Specifically Kills Activated Lymphocytes and Blocks Liver Damage in the Concanavalin A Hepatitis Model," <i>J. Exp. Med.</i> , 198:497-503 (2003) | |
| /L.S./ | A78 | Matsuoka et al., "A Novel Type of Cell Death of Lymphocytes Induced by a Monoclonal Antibody without Participation of Complement," <i>J. Exp. Med.</i> , 181:2007-2015 (1995) | |
| /L.S./ | A79 | Nishii, "CD22 antibody therapy," <i>Current Therapy</i> , 20:47-50 (2001) (English translation included) | |
| /L.S./ | A80 | Ohtomo et al., "Molecular Cloning and Characterization of a Surface Antigen Preferentially Overexpressed on Multiple Myeloma Cells," <i>Biochem. Biophys. Res. Commun.</i> , 258:583-591 (1999) | |
| /L.S./ | A81 | Oka, "Development of Novel Immunotoxin Using Recombinant Alpha-Sarcin and Its Application Treatment of Hematopoietic Tumor," <i>Sankyo Seimeい Kagaku Kenkyu Shinko Zaidan Kenkyu Hokokushu</i> , 12:46-56 (1998) (concise English explanation included) | |
| /L.S./ | A82 | Ono et al., "The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cyto-toxicity," <i>Mol. Immunol.</i> , 36:387-395 (1999) | |
| /L.S./ | A83 | Orita et al., "A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor," <i>Blood</i> , 105:562-566 (2005) | |

| | |
|--|-----------------|
| Examiner Signature | Date Considered |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | |
|--|--|---------------------------------------|-------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 14875-153US1 | Application No. 10/551,504 |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant Hiroyuki Tsunoda et al. | |
| | | Filing Date May 12, 2006 | Group Art Unit 1644 |

| Other Documents (include Author, Title, Date, and Place of Publication) | | |
|--|-----------|--|
| Examiner Initial | Desig. ID | Document |
| /L.S./ | A84 | Ozaki et al., "A Recombinant HLA Class I-Specific Single Chain Fv Diabody Induces Cell Death in Human Lymphoid Malignancies," <i>Blood</i> , 102:933a, Abstract No. 3474 (2003) |
| /L.S./ | A85 | Ozaki et al., "Humanized Anti-HM1.24 Antibody Mediates Myeloma Cell Cytotoxicity That Is Enhanced by Cytokine Stimulation of Effector Cells," <i>Blood</i> , 93:3922-3930 (1999) |
| /L.S./ | A86 | Ozaki et al., "Immunotherapy of Multiple Myeloma With a Monoclonal Antibody Directed Against a Plasma Cell-Specific Antigen, HM1.24," <i>Blood</i> , 90:3179-3186 (1997) |
| /L.S./ | A87 | Pettersen et al., "The TCR-Binding Region of the HLA Class I α_2 Domain Signals Rapid Fas-Independent Cell Death: A Direct Pathway for T Cell-Mediated Killing of Target Cells?" <i>J. Immunol.</i> , 160:4343-4352 (1998) |
| /L.S./ | A88 | Piétrí-Rouxel et al., "The biochemical effect of the naturally occurring Trp64 \rightarrow Arg mutation on human β 3-adrenoceptor activity," <i>Eur. J. Biochem.</i> , 247:1174-1179 (1997) |
| /L.S./ | A89 | Plückthun et al., "New protein engineering approaches to multivalent and bispecific antibody fragments," <i>Immunotechnology</i> , 3:83-105 (1997) |
| /L.S./ | A90 | Rossi et al., "Development of New Multivalent-bispecific Agents for Pretargeting Tumor Localization and Therapy," <i>Clin. Cancer Res.</i> , 9:3886s-3896s (2003) |
| /L.S./ | A91 | Sato et al., "CD22 Is Both a Positive and Negative Regulator of B Lymphocyte Antigen Receptor Signal Transduction: Altered Signaling in CD22-Deficient Mice," <i>Immunity</i> , 5:551-562 (1996) |
| /L.S./ | A92 | Scheurle et al., "Cancer Gene Discovery Using Digital Differential Display," <i>Cancer Res.</i> , 60:4037-4043 (2000) |
| /L.S./ | A93 | Smith et al., "Inhibition of T Cell Activation by a Monoclonal Antibody Reactive Against the α_3 Domain of Human MHC Class I Molecules," <i>J. Immunol.</i> , 153:1054-1067 (1994) |
| /L.S./ | A94 | Tahitis et al., "Biodistribution Properties of 111 Indium-labeled C-Functionalized <i>trans</i> -Cyclohexyl Diethylenetriaminepentaacetic Acid Humanized 3S193 Diabody and F(ab') $_2$ Constructs in a Breast Carcinoma Xenograft Model," <i>Clin. Cancer Res.</i> , 7:1061-1072 (2001) |
| /L.S./ | A95 | Tedder et al., "CD22, a B Lymphocyte-Specific Adhesion Molecule That Regulates Antigen Receptor Signaling," <i>Annu. Rev. Immunol.</i> , 15:481-504 (1997) |
| /L.S./ | A96 | Thilenius et al., "Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants," <i>Eur. J. Immunol.</i> , 27:1108-1114 (1997) |
| /L.S./ | A97 | Woodle et al., "Anti-Human Class I α_3 Domain-Specific Monoclonal Antibody Induces Programmed Cell Death in Murine Cells Expressing Human Class I MHC Transgenes," <i>Transplant. Proc.</i> , 30:1059-1060 (1998) |
| /L.S./ | A98 | Woodle et al., "Anti-Human Class I MHC Antibodies Induce Apoptosis by a Pathway That Is Distinct from the Fas Antigen-Mediated Pathway," <i>J. Immunol.</i> , 158:2156-2164 (1997) |
| /L.S./ | A99 | Woodle et al., "Class I MHC Mediates Programmed Cell Death in Human Lymphoid Cells," <i>Transplantation</i> , 64:140-146 (1997) |
| /L.S./ | A100 | Wu et al., "Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers," <i>Immunotechnology</i> , 2:21-36 (1996) |
| /L.S./ | A101 | Xiong et al., "Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 \times anti-CD3 bispecific diabody," <i>Cancer Lett.</i> , 177:29-39 (2002) |
| /L.S./ | A102 | Xu et al., "Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver," <i>Proc. Natl. Acad. Sci. USA</i> , 98:15089-15094 (2001) |

| | |
|--|-----------------------------------|
| Examiner Signature /Lorraine Spector/ | Date Considered 03/23/2009 |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |